Dishman Carbogen Amcis Limited (DCAL.BO)
INR 210.2
(1.13%)
INR 210.2
(1.13%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 23.12 Billion INR | 4.7% |
| 2022 | 22.08 Billion INR | 20.71% |
| 2021 | 18.29 Billion INR | 15.17% |
| 2020 | 15.88 Billion INR | 17.05% |
| 2019 | 13.57 Billion INR | 30.25% |
| 2018 | 10.42 Billion INR | -4.81% |
| 2017 | 10.94 Billion INR | 15.28% |
| 2016 | 9.49 Billion INR | 0.73% |
| 2015 | 9.42 Billion INR | 1.09% |
| 2014 | 9.32 Billion INR | -4.26% |
| 2013 | 9.74 Billion INR | 14.12% |
| 2012 | 8.53 Billion INR | 0.47% |
| 2011 | 8.49 Billion INR | 16.68% |
| 2010 | 7.28 Billion INR | -5.92% |
| 2009 | 7.73 Billion INR | 7.13% |
| 2008 | 7.22 Billion INR | 14.99% |
| 2007 | 6.28 Billion INR | 11.99% |
| 2006 | 5.6 Billion INR | 72.34% |
| 2005 | 3.25 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 23.12 Billion INR | 0.0% |
| 2023 Q2 | 23.07 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 23.12 Billion INR | 4.7% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 22.08 Billion INR | 20.71% |
| 2022 Q4 | 22.08 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 20.38 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 18.29 Billion INR | 15.17% |
| 2021 Q2 | 15.51 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 18.29 Billion INR | 0.0% |
| 2020 FY | 15.88 Billion INR | 17.05% |
| 2020 Q2 | 12 Billion INR | 0.0% |
| 2020 Q4 | 15.88 Billion INR | 0.0% |
| 2019 FY | 13.57 Billion INR | 30.25% |
| 2019 Q2 | 11.37 Billion INR | 0.0% |
| 2019 Q4 | 13.57 Billion INR | 0.0% |
| 2018 FY | 10.42 Billion INR | -4.81% |
| 2018 Q4 | 10.42 Billion INR | 0.0% |
| 2018 Q2 | 11.36 Billion INR | 0.0% |
| 2017 FY | 10.94 Billion INR | 15.28% |
| 2017 Q2 | 9.51 Billion INR | 0.0% |
| 2017 Q4 | 10.94 Billion INR | 0.0% |
| 2016 FY | 9.49 Billion INR | 0.73% |
| 2016 Q4 | 9.49 Billion INR | 0.0% |
| 2016 Q2 | 7.71 Billion INR | 0.0% |
| 2015 FY | 9.42 Billion INR | 1.09% |
| 2015 Q4 | 9.42 Billion INR | 0.0% |
| 2015 Q2 | 7.74 Billion INR | 0.0% |
| 2014 Q2 | 7.2 Billion INR | 0.0% |
| 2014 FY | 9.32 Billion INR | -4.26% |
| 2014 Q4 | 9.32 Billion INR | 0.0% |
| 2013 Q2 | 8.63 Billion INR | 0.0% |
| 2013 Q4 | 9.74 Billion INR | 0.0% |
| 2013 FY | 9.74 Billion INR | 14.12% |
| 2012 FY | 8.53 Billion INR | 0.47% |
| 2012 Q4 | 8.53 Billion INR | 0.0% |
| 2011 Q4 | 8.49 Billion INR | 0.0% |
| 2011 FY | 8.49 Billion INR | 16.68% |
| 2010 FY | 7.28 Billion INR | -5.92% |
| 2009 FY | 7.73 Billion INR | 7.13% |
| 2008 FY | 7.22 Billion INR | 14.99% |
| 2007 FY | 6.28 Billion INR | 11.99% |
| 2006 FY | 5.6 Billion INR | 72.34% |
| 2005 FY | 3.25 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 1.35 Billion INR | -1604.84% |
| Biocon Limited | 162.76 Billion INR | 85.792% |
| Blue Jet Healthcare Limited | 16.12 Million INR | -143272.607% |
| Concord Biotech Limited | 97.37 Million INR | -23649.178% |
| FERMENTA BIOTECH LIMITED | 1.32 Billion INR | -1648.382% |
| GENOMIC VALLEY BIOTECH LIMITED | - INR | -Infinity% |
| Lyka Labs Limited | 586.5 Million INR | -3843.045% |
| Panacea Biotec Limited | 209.9 Million INR | -10917.627% |
| SAMSRITA LABS LIMITED | 22.03 Million INR | -104865.505% |
| Servoteach Industries Limited | 5059.00 INR | -457125814.212% |
| SMS Lifesciences India Limited | 1 Billion INR | -2195.982% |
| Supriya Lifescience Limited | 54.88 Million INR | -42039.213% |
| Syngene International Limited | 5.55 Billion INR | -316.535% |
| TAKE Solutions Limited | 370.85 Million INR | -6135.944% |
| Titan Biotech Limited | 83.02 Million INR | -27752.919% |
| Transgene Biotek Limited | 140.01 Million INR | -16417.392% |
| Vanta Bioscience Limited | 609.53 Million INR | -3694.033% |